Article

Catalent's SMARTag ADC Stands Out In The Crowd Of HER2-Targeted Conjugates

Source: Catalent

By Penelope Drake, Ph.D., Head of R&D, Bioconjugates, Catalent Biologics

research-microscope-samples-iStock-1220382399

The steadily growing number of HER2-targeted antibody-drug conjugates (ADCs) in preclinical development is a testament to the success of the original anti-HER2 ADC, Kadcyla® (adotrastuzumab emtansine/T-DM1(1)), which comprises the trastuzumab antibody appended through a noncleavable linker to the potent microtubule inhibitor payload, maytansine. T-DM1 was the first approved ADC against a solid tumor indication(2), and its efficacy showed the promise of HER2-targeted therapies; follow-on molecules have been designed with the goal of improving upon this first-generation drug and thereby continue to raise the bar for patient outcomes. However, the sheer number of follow-on candidates makes it difficult to keep track of the state-of-the-art, and for those not immersed in the field, it can be hard to differentiate among the many iterations in order to find the true innovations in the crowd.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader